Vogenx closes $81.3M IPO at $13 per share, lists on Nasdaq
Vogenx Inc. closed its IPO of 6.25 million shares at $13.00 per share, raising approximately $81.3 million in gross proceeds. The stock began trading on the Nasdaq Capital Market under ticker VOGX. Jones Trading managed the deal, with an oversubscription option for 937,500 additional shares available for 45 days.
*this image is generated using AI for illustrative purposes only.
Vogenx Inc. (NASDAQ: VOGX) has completed its initial public offering, securing $81.3 million in gross proceeds before deducting underwriting discounts and other expenses. The clinical-stage biopharmaceutical company sold 6,250,000 shares of common stock at a public offering price of $13.00 per share. All shares were offered directly by Vogenx.
The company's common stock commenced trading on the Nasdaq Capital Market on August 12, 2026, under the ticker symbol "VOGX." The registration statement on Form S-1 (File No. 333-297487) was declared effective by the U.S. Securities and Exchange Commission on August 11, 2026.
Offering Details
Jones Trading Institutional Services LLC served as the sole book-running manager for the offering. In addition to the initial tranche, Vogenx granted underwriters a 45-day option to purchase up to an additional 937,500 shares at the public offering price, less applicable underwriting discounts and commissions.
| Metric | Detail |
|---|---|
| Shares Sold | 6,250,000 |
| Offer Price | $13.00 per share |
| Gross Proceeds | ~$81.3 million |
| Oversubscription Option | 937,500 shares (45-day window) |
| Lead Manager | Jones Trading |
Business Focus
Vogenx focuses on developing novel therapeutics for serious diseases linked to human metabolic dysfunctions, including post-bariatric hypoglycemia (PBH) and gastroparesis. Its lead product candidate, mizagliflozin, is an orally administered, minimally absorbed small molecule drug in development for PBH, gastroparesis, and GIP-dependent Cushing's Syndrome. The company licensed worldwide rights to mizagliflozin, excluding Japan, Korea, and Taiwan, from Kissei Pharmaceutical in 2021.
How will the $81.3 million in IPO proceeds specifically accelerate the clinical trial timelines for mizagliflozin across its three target indications?
What is the current status of the 45-day oversubscription option, and will exercising it significantly impact Vogenx's cash runway for future R&D milestones?
Given that Vogenx excluded Japan, Korea, and Taiwan from its license with Kissei Pharmaceutical, how might regional regulatory differences affect global commercialization strategies?
19
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
